Modeling early Parkinson's disease pathology with chronic low dose MPTP treatment

Restorative Neurology and Neuroscience

Volumn 31, Issue 2, 2013, Pages 155-167

  Korecka, Joanna A ^a   Eggers, Ruben ^a   Swaab, Dick F ^a   Bossers, Koen ^a   Verhaagen, Joost ^a  

^a NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

Author keywords

astrogliosis; dopaminergic neuron; dying back hypothesis; grid test; microgliosis; MPTP; substantia nigra; tyrosine hydroxilase

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; DOPAMINE; PROBENECID; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTOSIS; CONTROLLED STUDY; DISEASE MODEL; DRUG MEGADOSE; FOREFOOT; GLIOSIS; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LOW DRUG DOSE; MALE; NERVE CELL DEGENERATION; NERVE ENDING; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL;

ANIMALS; DISEASE MODELS, ANIMAL; MALE; MICE; MICE, INBRED C57BL; MOVEMENT; MPTP POISONING; NERVE DEGENERATION; NEURONS; PARKINSON DISEASE; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 84876351189     PISSN: 09226028     EISSN: 18783627     Source Type: Journal    
DOI: 10.3233/RNN-110222     Document Type: Article

References (47)

1. Ahmad, S.O., Park, J.H., Stenho-Bittel, L. & Lau, Y.S. (2009). Effects of endurance exercise on ventral tegmental area neurons in the chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and probenecid-treated mice. Neurosci Lett, 450(2), 102-105.
2. Alvarez-Fischer, D., Guerreiro, S., Hunot, S., Saurini, F., Marien, M., Sokoloff, P., Hirsch, E.C., Hartmann, A. & Michel, P.P. (2008). Modelling Parkinson-like neurodegeneration via osmotic minipump delivery of MPTP and probenecid. J Neurochem, 107(3), 701-711.
3. Barber-Singh, J., Seo, B.B., Nakamaru-Ogiso, E., Lau, Y.S., Matsuno-Yagi, A. & Yagi, T. (2009). Neuroprotective effect of long-term NDI1 gene expression in a chronic mouse model of Parkinson disorder. Rejuvenation Res, 12(4), 259-267.
4. Barcia, C., Fernandez, B.A., Poza, M. & Herrero, M.T. (2003). Parkinson's disease and inflammatory changes. Neurotox Res, 5(6), 411-418.
5. Beal, M.F. (2003). Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Ann N Y Acad Sci, 991, 120-131. (Pubitemid 36793808)
6. Betarbet, R., Sherer,T.B.&Greenamyre, J.T. (2002). Animal models of Parkinson's disease. Bioessays, 24(4), 308-318. (Pubitemid 34305686)
7. Bove, J., Prou, D., Perier,C.&Przedborski, S. (2005).Toxin-induced models of Parkinson's disease. NeuroRx, 2(3), 484-494. (Pubitemid 41444882)
8. Braak, H., Del, T.K., Rub, U., de Vos, R.A., Jansen Steur, E.N. & Braak, E. (2003). Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging, 24(2), 197-211. (Pubitemid 36007810)
9. Burke, R.E. & O'Malley, K. (2012). Axon degeneration in Parkinson's disease. Exp Neurol, published online ahead of print January 18, 2012, PMID: 22285449.
10. Cheng, H.C., Ulane, C.M. & Burke, R.E. (2010). Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol, 67(6), 715-725.
11. Chung, C.Y., Koprich, J.B., Siddiqi, H. & Isacson, O. (2009). Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy. J Neurosci, 29(11), 3365-3373.
12. Dauer, W. & Przedborski, S. (2003). Parkinson's disease: Mechanisms and models. Neuron, 39(6), 889-909. (Pubitemid 37130207)
13. Fleming, S.M., Delville, Y. & Schallert, T. (2005). An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: Antiparkinson effects of Sinemet and protective effects of methylphenidate. Behav Brain Res, 156(2), 201-213. (Pubitemid 39576060)
14. Gorell, J.M., Peterson, E.L., Rybicki, B.A. & Johnson, C.C. (2004). Multiple risk factors for Parkinson's disease. J Neurol Sci, 217(2), 169-174. (Pubitemid 38056551)
15. Greenamyre, J.T. & Hastings, T.G. (2004). Biomedicine. Parkinson's-divergent causes, convergent mechanisms. Science, 304(5674), 1120-1122. (Pubitemid 38661838)
16. Haehner, A., Hummel, T., Hummel, C., Sommer, U., Junghanns, S. & Reichmann, H. (2007). Olfactory loss may be a first sign of idiopathic Parkinson's disease. Mov Disord, 22(6), 839-842. (Pubitemid 46800106)
17. Hanisch, U.K. (2002). Microglia as a source and target of cytokines. Glia, 40(2), 140-155.
18. Hirsch, E.C., Breidert, T., Rousselet, E., Hunot, S., Hartmann, A. & Michel, P.P. (2003). The role of glial reaction and inflammation in Parkinson's disease. Ann N Y Acad Sci, 991, 214-228. (Pubitemid 36793816)
19. Jackson-Lewis, V. & Przedborski, S. (2007). Protocol for the MPTP mouse model of Parkinson's disease. Nat Protoc, 2(1), 141-151. (Pubitemid 47044700)
20. Jossan, S.S., Sakurai, E. & Oreland, L. (1989). MPTP toxicity in relation to age, dopamine uptake and MAO-B activity in two rodent species. Pharmacol Toxicol, 64(3), 314-318. (Pubitemid 19082345)
21. Langston, J.W., Forno, L.S., Tetrud, J., Reeves, A.G., Kaplan, J.A.& Karluk, D. (1999). Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine exposure. Ann Neurol, 46(4), 598-605. (Pubitemid 29466438)
22. Lau, Y.S., Patki, G., Das-Panja, K., Le, W.D. & Ahmad, S.O. (2011). Neuroprotective effects and mechanisms of exercise in a chronic mouse model of Parkinson's disease with moderate neurodegeneration. Eur J Neurosci, 33(7), 1264-1274.
23. Lau, Y.S., Trobough, K.L., Crampton, J.M. & Wilson, J.A. (1990). Effects of probenecid on striatal dopamine depletion in acute and long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice. Gen Pharmacol, 21(2), 181-187. (Pubitemid 20097400)
24. Li, L.H., Qin, H.Z., Wang, J.L., Wang, J., Wang, X.L. & Gao, G.D. (2009a). Axonal degeneration of nigra-striatum dopaminergic neurons induced by 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine in mice. J Int Med Res, 37(2), 455-463.
25. Li,Y., Liu,W., Oo,T.F.,Wang, L.,Tang,Y., Jackson-Lewis,V., Zhou, C., Geghman, K., Bogdanov, M., Przedborski, S., Beal, M.F., Burke, R.E. & Li, C. (2009b). Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat Neurosci, 12(7), 826-828.
26. McGeer, P.L. &McGeer, E.G. (2008). Glial reactions in Parkinson's disease. Mov Disord, 23(4), 474-483.
27. Meredith, G.E. & Kang, U.J. (2006). Behavioral models of Parkinson's disease in rodents: A new look at an old problem. Mov Disord, 21(10), 1595-1606. (Pubitemid 44742185)
28. Meredith, G.E., Totterdell, S., Beales, M. & Meshul, C.K. (2009). Impaired glutamate homeostasis and programmed cell death in a chronic MPTP mouse model of Parkinson's disease. Exp Neurol, 219(1), 334-340.
29. Meredith, G.E., Totterdell, S., Petroske, E., Santa, C.K., Callison, R.C. Jr. & Lau, Y.S. (2002). Lysosomal malfunction accompanies alpha-synuclein aggregation in a progressive mouse model of Parkinson's disease. Brain Res, 956(1), 156-165. (Pubitemid 35335568)
30. Meredith, G.E., Totterdell, S., Potashkin, J.A. & Surmeier, D.J. (2008). Modeling PD pathogenesis in mice: Advantages of a chronic MPTP protocol. Parkinsonism Relat Disord, 14(Suppl 2), S112-S115.
31. Nicotra, A. & Parvez, S. (2002). Apoptotic molecules and MPTPinduced cell death. Neurotoxicol Teratol, 24(5), 599-605. (Pubitemid 35013521)
32. Novikova, L., Garris, B.L., Garris, D.R. & Lau, Y.S. (2006). Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1- methyl-4-phenyl-1,2,3,6- tetrahydropyridine/probenecid model of Parkinson's disease. Neuroscience, 140(1), 67-76. (Pubitemid 43668437)
33. Paxinos, G.&Franklin, K.B.J. (2001). The Mouse Brain in in Stereotaxic Coordinates. Academic Press: New York.
34. Petroske, E., Meredith, G.E., Callen, S., Totterdell, S. & Lau, Y.S. (2001). Mouse model of Parkinsonism: A comparison between subacute MPTP and chronic MPTP/probenecid treatment. Neuroscience, 106(3), 589-601. (Pubitemid 32925247)
35. Przedborski, S., Jackson-Lewis, V., Naini, A.B., Jakowec, M., Petzinger, G., Miller, R. & Akram, M. (2001). The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): A technical review of its utility and safety. J Neurochem, 76(5), 1265-1274. (Pubitemid 32198231)
36. Ricaurte, G.A., Irwin, I., Forno, L.S., DeLanney, L.E., Langston, E. & Langston, J.W. (1987). Aging and 1-methyl-4-phenyl- 1,2,3,6- tetrahydropyridine-induced degeneration of dopaminergic neurons in the substantia nigra. Brain Res, 403(1), 43-51. (Pubitemid 17009738)
37. Schintu, N., Frau, L., Ibba, M., Caboni, P., Garau, A., Carboni, E. & Carta, A.R. (2009a). PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease. Eur J Neurosci, 29(5), 954-963.
38. Schintu, N., Frau, L., Ibba, M., Garau, A., Carboni, E. & Carta, A.R. (2009b). Progressive dopaminergic degeneration in the chronic MPTPp mouse model of Parkinson's disease. Neurotox Res, 16(2), 127-139.
39. Schneider, J.S., Rothblat, D.S. & DiStefano, L. (1994). Volume transmission of dopamine over large distancesmaycontribute to recovery from experimental parkinsonism. Brain Res, 643(1-2), 86-91. (Pubitemid 24115080)
40. Schober, A. (2004). Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res, 318(1), 215-224. (Pubitemid 39366054)
41. Schwarting, R.K., Sedelis, M., Hofele, K., Auburger, G.W. & Huston, J.P. (1999). Strain-dependent recovery of open-field behavior and striatal dopamine deficiency in the mouse MPTP model of Parkinson's disease. Neurotox Res, 1(1), 41-56.
42. Sedelis, M., Schwarting, R.K. & Huston, J.P. (2001). Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav Brain Res, 125(1-2), 109-125. (Pubitemid 33000449)
43. Tillerson, J.L. &Miller, G.W. (2003). Grid performance test to measure behavioral impairment in the MPTP-treated-mouse model of parkinsonism. J Neurosci Methods, 123(2), 189-200. (Pubitemid 36279413)
44. Tofaris, G.K., Garcia, R.P., Humby, T., Lambourne, S.L., O'Connell, M., Ghetti, B., Gossage, H., Emson, P.C., Wilkinson, L.S., Goedert, M. & Spillantini, M.G. (2006). Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1- 120): Implications for Lewy body disorders. J Neurosci, 26(15), 3942-3950. (Pubitemid 44315414)
45. Weihmuller, F.B., Bruno, J.P., Neff, N.H. & Hadjiconstantinou, M. (1990). Dopamine receptor plasticity following MPTP-induced nigrostriatal lesions in the mouse. Eur J Pharmacol, 180(2-3), 369-372. (Pubitemid 20170877)
46. Xu, G., Xiong, Z., Yong, Y., Wang, Z., Ke, Z., Xia, Z. & Hu, Y. (2010). Catalpol attenuates MPTP induced neuronal degeneration of nigral-striatal dopaminergic pathway in mice through elevating glial cell derived neurotrophic factor in striatum. Neuroscience, 167(1), 174-184.
47. Yurek, D.M., Deutch, A.Y., Roth, R.H.&Sladek, JR Jr (1989). Morphological, neurochemical, and behavioral characterizations associated with the combined treatment of diethyldithiocarbamate and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine in mice. Brain Res, 497(2), 250-259. (Pubitemid 19226409)